Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections

EP4761755A1Pending Publication Date: 2026-06-24UNIV OF MARYLAND
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
UNIV OF MARYLAND
Filing Date
2024-08-15
Publication Date
2026-06-24

AI Technical Summary

Technical Problem

Current vaccines for Klebsiella pneumoniae and Pseudomonas aeruginosa infections are limited in their effectiveness due to the poor immunogenicity of T cell-independent polysaccharide antigens and the lack of functional activity of antibodies against certain strains.

Method used

Development of a broad-spectrum conjugate vaccine that combines glycosylated native FlaA flagellin protein of Pseudomonas with surface polysaccharide antigens and/or core oligosaccharides of Klebsiella, along with a recombinant FlaB flagellin protein, to enhance immune response and antibody production.

Benefits of technology

The vaccine elicits robust antibody responses that are protective against experimental infections, reducing bacterial motility and providing functional activity against a wide range of Klebsiella and Pseudomonas strains.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024042585_20022025_PF_FP_ABST
    Figure US2024042585_20022025_PF_FP_ABST
Patent Text Reader

Abstract

The present invention is drawn to conjugates comprising a glycosylated native FlaA flagellin protein of Pseudomonas and Klebsiella surface polysaccharide antigens, such as Klebsiella pneumoniae O polysaccharides from serovars O1, O2a, O2a,c, O3, O4, O5, O7, O8 and O12. The present invention also provides pharmaceutical compositions comprising the same and methods of inducing an immune response in subjects by administering the compositions.
Need to check novelty before this filing date? Find Prior Art